Ensure Safe Use of Sulfonylureas for Type 2 Diabetes

January 2018

Patients will continue to be admitted on sulfonylureas despite all the hype and TV ads about newer drugs for type 2 diabetes.

The spotlight has been on empagliflozin (Jardiance), canagliflozin (Invokana), and liraglutide (Victoza) as options to add to metformin...since they reduce CV risk in certain diabetes patients.

And some clinicians are wondering if sulfonylureas should still be considered...since they can cause hypoglycemia and weight gain.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote